** Shares of drug developer Atara Biotherapeutics ATRA.O fall 4.6% to $6.27 premarket
** Co says the US FDA has placed a clinical hold on trials testing its experimental cancer cell therapies
** The hold applies to studies of co's experimental cancer therapies, tabelecleucel, and ATA3219
** Co says the hold is related to the issues observed at a third-party manufacturing facility
** The FDA last week declined to approve its cancer therapy tabelecleucel to treat patients with a rare cancer that develops after organ or stem cell transplants, due to third-party manufacturing concerns
** "Atara and FDA have discussed and agreed upon the actions necessary to release the clinical holds"- ATRA
** Co says it has paused enrollment of new participants in the trials; adding that some participants "who have the potential to derive clinical benefit" can continue to receive treatment
** Up last close, stock had fallen 63.2% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.